Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, and Lovell Government Services, Inc. ("Lovell"), a Service-Disabled Veteran-Owned Company ("SDVOSB") specializing in federal healthcare distribution, today announced a distribution, co-marketing and strategic partnership designed to support the introduction of Bluejay’s products into the U.S. federal healthcare market following applicable U.S. Food and Drug Administration ("FDA") clearance or other required regulatory authorization.

The partnership is designed to establish a scalable federal market access and procurement infrastructure in advance of potential commercialization, positioning Bluejay to efficiently pursue opportunities across some of the largest government-operated healthcare systems in the United States, subject to applicable FDA clearance or other required regulatory authorization for its products.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.